

ashm DECISION MAKING IN HEPATITIS C

1 When To Test

2 Test/s, Results and Actions

Clinical Indicators

- Abnormal liver function tests (LFTs) (males, ALT \ge 30 U/L; females, ALT \ge 19 U/L)
- Jaundice

Presence of Risk Factors


- Injecting drug use (current/ever)
- Sharing of snorting equipment
- Born in high prevalence region^
- Blood transfusions and blood products before 1990 in Australia
- Unsterile tattooing/body piercing
- Unsterile medical/dental procedures/blood transfusions in high prevalence countries
- Time in prison
- Needlestick injury
- Mother to child transmission
- Sexual transmission in men who have sex with men (MSM)
- Sexual transmission in those who are HIV positive
- People living with HIV or HBV infection
- ^Africa, the Middle East (in particular Egypt), the Mediterranean, Eastern Europe, and South Asia

Other

- Initiating PrEP
- When someone requests a test

When gaining informed consent before testing, discuss:

- Reason for test
- · Availability of curative treatment



*If high level suspicion also consider requesting reflexive HCV RNA (ordering HCV Ab + HCV PCR if HCV Ab is positive) + LFTs

 \ominus HCV



ashm DECISION MAKING IN HEPATITIS C

3 Pre-Treatment Assessment

Baseline screening after positive HCV PCR

- □ LFTs (including AST) and INR
- □ Full Blood Count
- □ Urea, electrolytes, creatinine

Assess liver fibrosis: cirrhotic status

- □ Signs of chronic liver disease (spider naevi, palmar erythema, jaundice, encephalopathy, hepatomegaly, splenomegaly, ascites, peripheral oedema)
- □ Non-invasive assessment of fibrosis: 🙆
 - Serum biomarkers such as APRI (<1.0 means cirrhosis unlikely). Calculator available hepatitisc.uw.edu/page/clinical-calculators/apri
 - Elastography assessment e.g. Fibroscan® (>12.5 kPa consistent with cirrhosis)

Check for other causes of liver disease

- Check for viral coinfection:
 HIV Ab/Ag
 - Hepatitis A check hep A IgG; vaccinate if negative
 - Hepatitis B check HBsAg, anti-HBc and anti-HBs; vaccinate if all negative
- □ Heavy alcohol intake
- □ Fatty liver disease check weight, BMI

Check for other major co-morbidities

🗆 Renal impairment (eGFR < 50) 🙆

Review previous HCV treatment

 Choice/length of treatment may be influenced by prior HCV treatment experience/response

Consider pregnancy and contraception

 HCV treatment not recommended for use in pregnant or lactating women

For more information www.hepcguidelines.org.au

SOF/VEL = Sofosbuvir/Velpatasvir; GLE/PIB = Glecaprevir/Pibrentasvir @ASHM 2023 ISBN: 978-1-921850-67-7 Last updated: November 2024

4 Treatment

Recommendation for treatment now includes all people with a risk factor for hepatitis C transmission who are found to have detectable HCV RNA in plasma or whole blood, regardless of the duration of infection.

Is your patient likely to have cirrhosis? (APRI ≥ 1.0 or Fibroscan® > 12.5 kPa)							
C] Yes			No			
Discuss with specialist [#]	n or refer to a						
Has your patient received previous treatment for HCV?							
C	☐ Yes			No			
Discuss with or refer to a specialist [#]							
Treatment	Dosage	Duration if no cirrhosis present	-	ion if ensated osis (Child			

			no cirrhosis present	compensated cirrhosis (Child Pugh A) present
	SOF/VEL~ (Epclusa®)	400/100mg Once-daily (1 pill)	12 weeks	12 weeks
	GLE/PIB~ (Maviret®)	100/40mg per pill Once-daily (3 pills)	8 weeks	8 weeks ⁺

□ Check for drug-drug interactions at hep-druginteractions.org

□ Call the PBS Authority Script Line (1800 020 613) for approval

Consult with your local specialist or complete the online remote consultation form at reach-C.ashm.org.au (turn-around time <24 hours).

All patients with cirrhosis or prior HCV treatment experience should be reviewed by someone experienced in hepatitis C treatment. If cirrhosis is suspected (APRI ≥ 1.0 or elastography > 12.5 kPa), further evaluation is required before commencing treatment.

† A treatment duration of 12 weeks may be considered for patients with compensated cirrhosis at the discretion of the prescriber.

5 Monitoring

treatment

Monitoring while on

- Generally not required but approach should be individualised
- Side effects of HCV treatment are generally minimal
- Dose interruptions should be managed according to duration and DAA therapy completed (Refer to Hepatitis C Consensus Statement)

4-12 weeks post 🙆 treatment

 Opportunistic testing: HCV RNA to confirm cure (sustained virological response SVR4 = cure)
 LFTs

6 Follow Up

If your patient has no cirrhosis and normal

⊖∙HCV

LFT results (males, ALT< 30 U/L; females, ALT < 19 U/L) ALT = alanine aminotransferase No clinical follow-up for HCV required

If your patient has ongoing risk factors

Annual HCV RNA test. If re-infected, offer re-treatment and harm reduction strategies

If your patient has abnormal LFT results 😣

(males, ALT \ge 30 U/L; females, ALT \ge 19 U/L) Evaluate for other causes of liver disease and refer to specialist for review

If your patient has cirrhosis 🙆

Refer to specialist. Patients with cirrhosis require long-term monitoring:

- 6-monthly abdominal ultrasound (hepatocellular carcinoma screening)
- Consideration of screening for oesophageal varices
- Osteoporosis: 2-yearly DEXA scans and monitor serum vitamin D
- Assess risk of clinically significant portal hypertension (elastography, PLT)

CONSULT WITH A SPECIALIST IF:

Pre-treatment

- Prior treatment failure of HCV treatmen Cirrhosis is present or likely – APRI ≥1
- and elastography score not available; elastography >12.5kPa
- Coinfected with HIV or HBV
- Renal impairment (eGFR < 50)
 Complex drug interactions
- Complex co-morbidities

- Not comfortable prescribing HCV treatment
- Paediatric population

During treatment

• Major medication side events

Post-treatment

- RNA positive 12 weeks post treatment
- Abnormal LFTs at SVR1

Disclaimer: Guidance provided on this resource is based on guidelines and best-practices at the time of publication. This quick-reference guide is not intended to be a comprehensive list of all available options. Refer to the General Statement for Drugs for the Treatment of Hepatitis C for all current PBS-listed regimens.